Stockscreener 앱 받기
5.20
0.39%
0.02
시간 외 거래:
29.72
24.52
+471.54%
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Relmada Therapeutics Inc (RLMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Relmada Therapeutics Inc (RLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RLMD|Relmada Therapeutics Inc|Price:5.180|Chg%:-0.020 - TradingKey
Relmada Therapeutics Inc Revenue Breakdown – FWB:4E2 - TradingView
Relmada Therapeutics Inc (RLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Relmada Therapeutics Inc (RLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Relmada Therapeutics Inc (RLMD) Institutional Confidence - TradingKey
Relmada Therapeutics schedules Q2 2026 financial results call - Bitget
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 - Investing News Network
Relmada Therapeutics to announce Q2 2026 financial results - scanx.trade
Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19 - Moomoo
RELMADA THERAPEUTICS INC (RLMD) Stock Chart - ChartMill
Relmada Therapeutics (RLMD) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Relmada Therapeutics Inc. (RLMD) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Relmada's cancer drug candidate sparks fresh bullish call - MSN
RLMDRelmada Therapeutics Inc Options - Finviz
Relmada Therapeutics (RLMD) Faces Minor Pullback, Testing Key Support LevelsAAII Bullish - dars.gov.et
RLMD Q1 2026 Earnings: Reported Loss Exceeds Expectations, Stock DropsDiluted EPS Report - DonanımHaber
Enterprise value to EBITDA forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Enterprise value to revenue forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Price to book forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2500 Growth Benchmark - marketscreener.com
Relmada Therapeutics Joins Russell 2000, Russell 3000 Indexes - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2000 Index - marketscreener.com
Relmada Therapeutics added to Russell 2000 and 3000 indexes - Investing.com
Relmada Therapeutics added to Russell 2000 and 3000 indexes By Investing.com - Investing.com Australia
Relmada Therapeutics (RLMD) Joins Russell 2000 and 3000 Indices - GuruFocus
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2000 Growth Benchmark - marketscreener.com
Price to earnings forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 3000E Index - marketscreener.com
Price to sales forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell Microcap Index - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 3000 Growth Benchmark - marketscreener.com
RLMD Jumps As HC Wainwright Launches Buy Coverage - timothysykes.com
RLMD Jumps As H.C. Wainwright Launches Bullish Coverage - timothysykes.com
Relmada Therapeutics Inc Actuals & Estimates (NASDAQ:RLMD) - TradingView
RLMD Forecast — Price Target — Prediction for 2027 - TradingView
4E2 Forecast — Price Target — Prediction for 2027 - TradingView
RLMD Q1 2026 Earnings: EPS Miss as Stock Edges Higher on Pipeline FocusEPS Estimate Trend - dars.gov.et
Relmada Therapeutics Inc (NASDAQ: RLMD) Share Price, RLMD Stock News, RLMD Share Price & Updates - Kalkine
Relmada Therapeutics stock maintained at Buy by H.C. Wainwright - Investing.com
H.C. Wainwright Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
H.C. Wainwright Reiterates Buy Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider
Form 13G Relmada Therapeutics For: 22 June By Investing.com - Investing.com Australia
Millennium Group reports 4.57M Relmada shares (NASDAQ: RLMD) in 13G - Stock Titan
Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
1.97%
0.83%
자본화:
|
볼륨(24시간):